Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
Protein & Cell
; (12): 866-877, 2016.
Article
Dans En
| WPRIM
| ID: wpr-757362
Responsable en Bibliothèque :
WPRO
ABSTRACT
Antibody-based PD-1/PD-L1 blockade therapies have taken center stage in immunotherapies for cancer, with multiple clinical successes. PD-1 signaling plays pivotal roles in tumor-driven T-cell dysfunction. In contrast to prior approaches to generate or boost tumor-specific T-cell responses, antibody-based PD-1/PD-L1 blockade targets tumor-induced T-cell defects and restores pre-existing T-cell function to modulate antitumor immunity. In this review, the fundamental knowledge on the expression regulations and inhibitory functions of PD-1 and the present understanding of antibody-based PD-1/PD-L1 blockade therapies are briefly summarized. We then focus on the recent breakthrough work concerning the structural basis of the PD-1/PD-Ls interaction and how therapeutic antibodies, pembrolizumab targeting PD-1 and avelumab targeting PD-L1, compete with the binding of PD-1/PD-L1 to interrupt the PD-1/PD-L1 interaction. We believe that this structural information will benefit the design and improvement of therapeutic antibodies targeting PD-1 signaling.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Anatomopathologie
/
Lymphocytes T
/
Transduction du signal
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Allergie et immunologie
/
Anticorps monoclonaux humanisés
/
Antigène CD274
/
Récepteur-1 de mort cellulaire programmée
/
Anticorps monoclonaux
Limites du sujet:
Humans
langue:
En
Texte intégral:
Protein & Cell
Année:
2016
Type:
Article